Product Information
GALANTAMINE ER 8 MG CAPSULE is a generic product labeled by Aurobindo Pharma Limited, priced at $0.8024 per EA under NDC 65862074430. Its NADAC has been published 501 times since Mar 1, 2017.
FDA first approved this application on Aug 5, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Galantamine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
8 mg/1
Manufacturer
Aurobindo Pharma LimitedNDC
65862074430
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
GALANTAMINE HYDROBROMIDEApproval Type
Generic (ANDA)
FDA Application
ANDA204895FDA Approved
8/5/2016
TE Code
AB
On Market Since
8/5/2016
Pharmacological Classes
Price Statistics
The NADAC for GALANTAMINE ER 8 MG CAPSULE has been published 501 times since Mar 1, 2017, and over the history we have for it it has declined 52.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.8024 per EA |
|---|---|
| All-time high | $2.2671 (Sep 11, 2019) |
| All-time low | $0.6790 (May 22, 2024) |
| 52-week high | $0.9246 |
| 52-week low | $0.7782 |
| Median price | $1.2303 |
| Average price | $1.2801 |
| Largest weekly change | +84.5% (Jul 21, 2021) |
| Weeks tracked | 501 |
| Tracking since | Mar 1, 2017 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Galantamine market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurobindo Pharma Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Galantamine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cholinesterase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GALANTAMINE ER 8 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for GALANTAMINE ER 8 MG CAPSULE, manufactured by Aurobindo Pharma Limited, is $0.8024 per EA (NDC 65862074430), effective Sep 30, 2026.
How has the price of GALANTAMINE ER 8 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for GALANTAMINE ER 8 MG CAPSULE has declined 52.2%. It has been tracked across 501 weekly CMS publications since Mar 1, 2017.
What are the highest and lowest recorded NADAC prices for GALANTAMINE ER 8 MG CAPSULE?
Since Mar 1, 2017, the NADAC for GALANTAMINE ER 8 MG CAPSULE has ranged from a low of $0.6790 (May 22, 2024) to a high of $2.2671 (Sep 11, 2019), with a median of $1.2303 per EA.
Are there cheaper alternatives to GALANTAMINE ER 8 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of GALANTAMINE ER 8 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures GALANTAMINE ER 8 MG CAPSULE?
GALANTAMINE ER 8 MG CAPSULE (NDC 65862074430) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.